Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: an expert agreement.
about
Confirmatory Trials in the Evaluation of Anticancer Medicinal Products in Man--PFS2: A Measure of Therapeutic Action-At-A-DistanceMetastatic renal cell carcinoma: update on epidemiology, genetics, and therapeutic modalitiesEvaluation of second-line and subsequent targeted therapies in metastatic renal cell cancer (mRCC) patients treated with first-line cediranib.More than 10 years survival with sequential therapy in a patient with advanced renal cell carcinoma: a case report.Sunitinib re-challenge in advanced renal-cell carcinoma.Kinome expression profiling identifies IKBKE as a predictor of overall survival in clear cell renal cell carcinoma patients.A retrospective study of predictive factors for unexpectedly prolonged or shortened progression-free survival and overall survival among patients with metastatic renal cell carcinoma who received first-line targeted therapyA streamlined search technology for identification of synergistic drug combinations.Low-dose angiostatic tyrosine kinase inhibitors improve photodynamic therapy for cancer: lack of vascular normalization.Axitinib in metastatic renal cell carcinoma: single center experience.Sequential therapy in metastatic clear cell renal carcinoma: TKI-TKI vs TKI-mTOR.The clinical potential of temsirolimus in second or later lines of treatment for metastatic renal cell carcinoma.Metastatic renal cell carcinoma change vascularity.Recommendations on managing lenvatinib and everolimus in patients with advanced or metastatic renal cell carcinoma.
P2860
Q26782138-D1E84766-0D8F-4031-ACDF-E5FD06FBD349Q26852437-02C4CF7D-2319-46DA-A3EF-396B50FB4AB4Q34777424-BCE0D600-EA35-4D7E-BFB1-1DE8F4C948AAQ34886490-E4EFDC47-944A-40CC-A373-7EC8003E0426Q35678358-65289E18-A0A9-44F0-8E89-3CB27AF7D531Q35883559-4281F902-FE28-4252-879E-24362027DCF2Q36092829-6C275756-E3AD-4A07-B2E7-9543024DD48CQ36101810-30E817D9-0714-4743-A6D6-76CEB2C20234Q37638911-66B8EE82-99F1-453F-AFEF-D5E0000F7731Q37657679-FEE10770-9C02-4013-B67A-F34E6EE755A3Q38068584-1F3FB50F-CBFC-4F1F-B425-C005E3C8F212Q38136287-1902B7B8-E17A-4367-8F9B-CE62480D6807Q42273149-DC8E6DAC-2F0B-485F-A2B1-D3716CEB8415Q50049497-D159CCC4-4C48-475B-BB78-796DDCD41A2D
P2860
Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: an expert agreement.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 07 July 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Maximising the duration of dis ...... d agents: an expert agreement.
@en
Maximising the duration of dis ...... d agents: an expert agreement.
@nl
type
label
Maximising the duration of dis ...... d agents: an expert agreement.
@en
Maximising the duration of dis ...... d agents: an expert agreement.
@nl
prefLabel
Maximising the duration of dis ...... d agents: an expert agreement.
@en
Maximising the duration of dis ...... d agents: an expert agreement.
@nl
P2093
P2860
P1433
P1476
Maximising the duration of dis ...... d agents: an expert agreement.
@en
P2093
C Linassier
D Berthold
J P Maroto
K Papazisis
M De Santis
P2860
P2888
P304
P356
10.1007/S12032-011-0016-8
P577
2011-07-07T00:00:00Z